KIT mutations in mastocytosis and their potential as therapeutic targets.

Abstract excerpt

Deregulation of the KIT receptor TK by the prevalent activation loop mutation D816V has served as a focal point in therapeutic strategies aimed curbing neoplastic mast cell growth. Perhaps the most important development in this era of targeted therapy, and certainly relevant to KIT-driven diseases like mastocytosis, is the realization that small molecule inhibitors with varied chemical structure (eg, PKC412,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Chronic Myeloid Leukemia Treatments
• Share to Eosinophilic Disorders and Syndromes